NCT04601441View on ClinicalTrials.gov

Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan

PHASE4UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 6, 2020

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
Metastatic Castration-sensitive Prostate Cancer
Interventions
DRUG

Apalutamide

Apalutamide 240 mg administered orally once a day as four 60 mg tablets

Trial Locations (1)

589-851

RECRUITING

Kindai University Hospital, Ōsaka-sayama

Sponsors
All Listed Sponsors
collaborator

Janssen Pharmaceutical K.K.

INDUSTRY

lead

Kindai University

OTHER